ArticleCurrent issues in molecular biology2026
Cross-Cohort, Renal Compartment-Aware Transcriptomic Assessment of Lycii Fructus-Annotated Targets in Diabetic Kidney Disease.
Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Diabetic kidney disease (DKD) differs transcriptionally across renal compartments. We assessed whether Lycii Fructus-annotated targets showed reproducible DKD-associated changes and enrichment beyond matched expectations. Linked glomerular (GSE30528) and tubulointerstitial (GSE30529) cohorts were used for discovery; GSE96804 and platform-specific GSE104954 subsets provided external assessment. Phenotype-independent probe aggregation preceded limma analysis. Of 106 standardized HERB targets, 91 were measurable. Specificity was tested by hypergeometric analysis and 10,000 expression- and publication-matched permutations; external evidence was graded symmetrically. Thirty-six targets met the primary criterion in at least one compartment, but the target set was not enriched. CASP8 and VEGFA met Tier A external criteria, whereas ADRB2 and SLC6A2 met Tier B criteria. At the stricter |log
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.